Acadia Pharmaceuticals Inc. (ACAD) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-02-26

Business type: Asset play

How it makes money

Acadia's core drugs generated $1,071.5 million in sales during 2025.

The company generates revenue through its neurological and rare disease franchises. Sales are driven by the number of patients diagnosed and how often physicians prescribe the treatments.

What protects it: the moat

Management claims its products have a competitive advantage because they are the only approved treatments for their conditions.

The company's market position relies on its status as the sole provider of certain therapies. It claims its products are the first and only drugs approved by the FDA for their respective medical uses.

What growth costs

The company must reinvest in research and development to grow its business.

To expand, the company plans to develop its existing portfolio and find new rare disease opportunities. This involves expanding its pipeline and engaging in strategic business development. The filing does not state the specific costs for these activities.

What could damage it

If insurance coverage or reimbursement levels change, physicians may stop prescribing the drugs.

The company's revenue is vulnerable to changes in how third-party payors handle costs. If coverage is not provided or reimbursement is inadequate, physicians may stop prescribing the products, which would permanently impair earnings.

About Acadia Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Other companies in Biotechnology